Sugi Predict

Sugi Predict / Compounds / SCHEMBL274388

SCHEMBL274388

SCHEMBL274388

Cc1cc(C[C@H](N)C(=O)O)ccc1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 7/20 0.73
▸ USP2 O75604 3/20 0.73
▸ PTGS1 P23219 2/20 0.73
▸ KDM4E B2RXH2 2/20 0.73
▸ ALOX15 P16050 2/20 0.73
▸ RECQL P46063 2/20 0.73
▸ HIF1A Q16665 2/20 0.73
▸ HSD17B10 Q99714 2/20 0.73
▸ TDP1 Q9NUW8 2/20 0.73
▸ EGFR P00533 1/20 0.73
▸ LCK P06239 1/20 0.73
▸ FYN P06241 1/20 0.73
▸ ADORA3 P0DMS8 1/20 0.73
▸ HTR2A P28223 1/20 0.73
▸ PTGS2 P35354 1/20 0.73
▸ THRB P10828 4/20 0.61
▸ THRA P10827 3/20 0.61
▸ PKM P14618 3/20 0.53
▸ ALPI P09923 1/20 0.53
▸ XIAP P98170 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274387 1.00 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL31263758 1.00 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL6154805 1.00 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL7411743 0.94 SLC7A5 (0.65) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL12799629 0.88 ALOX15 (0.56) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL9952430 0.87 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL9952434 0.87 SLC7A5 (0.73) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL12656312 0.86 SLC1A1 (0.59) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL31734665 0.86 SLC7A5 (0.62) SLC7A5USP2PTGS1KDM4EALOX15
SCHEMBL2778612 0.86 SLC7A5 (0.62) SLC7A5USP2PTGS1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023182469-A1 METHOD FOR PRODUCING METHYL PHENOL 三菱ケミカル株式会社 2023-09-28 — — WO claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 — — CN claimed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 — — US claimed
CN-110885358-A Vaccine for preventing tumor recurrence and metastasis and application method thereof 浙江爱睦世医学科技有限公司 2020-03-17 — — CN claimed
CN-110857314-A Active polypeptide, polypeptide derivative, composition and using method thereof 许洋 2020-03-03 — — CN claimed
US-8642801-B2 Methods and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2014-02-04 — — US claimed
US-12637441-B2 Prodrugs of the tyrosine kinase inhibitor for treating cancer Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-05-26 — — US disclosed
US-20260125722-A1 METHOD FOR PRODUCING METHYL COMPOUND MITSUBISHI CHEMICAL CORPORATION (JP) 2026-05-07 — — US disclosed
US-12595260-B2 Stable heavy isotopes in amide functional groups and uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-04-07 — — US disclosed
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-02-17 — — US disclosed
EP-4692361-A1 METHOD FOR PRODUCING METHYL COMPOUND Mitsubishi Chemical Corporation (JP) 2026-02-11 — — EP disclosed
EP-4692363-A1 METHOD FOR PRODUCING METHYL COMPOUND Mitsubishi Chemical Corporation (JP) 2026-02-11 — — EP disclosed
US-20260035342-A1 ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES AND USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-02-05 — — US disclosed
WO-1999002175-A1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO., INC. (US) 1999-01-21 — — WO disclosed
EP-0855910-A1 CONJUGATES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA Merck & Co., Inc. (US) 1998-08-05 — — EP disclosed
EP-0853483-A1 NOVEL PEPTIDES Merck & Co., Inc. (US) 1998-07-22 — — EP disclosed
WO-1998018493-A2 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO., INC. (US) 1998-05-07 — — WO disclosed
WO-1998010651-A1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO., INC. (US) 1998-03-19 — — WO disclosed
WO-1997014416-A1 CONJUGATES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA MERCK & CO., INC. (US) 1997-04-24 — — WO disclosed
WO-1997012624-A1 NOVEL PEPTIDES MERCK & CO., INC. (US) 1997-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125722-A1 METHOD FOR PRODUCING METHYL COMPOUND GNMT, MTR, BHMT SLC7A5 315/4885USP2 3326/4885PTGS1 2179/4885
US-12637441-B2 Prodrugs of the tyrosine kinase inhibitor for treating cancer EGFR, ERBB2, MET SLC7A5 166/4885USP2 1618/4885PTGS1 2846/4885
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof SOST, FUT6, SLC5A1 SLC7A5 351/4885USP2 4743/4885PTGS1 592/4885
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP SLC7A5 21/4885USP2 1463/4885PTGS1 3737/4885
US-20260035342-A1 ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES AND USES THEREOF APP, PSEN1, BACE1 SLC7A5 36/4885USP2 3558/4885PTGS1 1963/4885
US-12595260-B2 Stable heavy isotopes in amide functional groups and uses thereof SLC10A1, SLC9A1, SLC10A6 SLC7A5 29/4885USP2 4053/4885PTGS1 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.